← Back to patent-cliff list
Irpagratinib
Tier C — Watch / tradeIrpagratinib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGFR4
Indications (approved)：Hepatocellular carcinoma, Solid tumour, Liver cancer
Regional status
US
Phase I
2020-02-26
EU
-
China
Phase II
2021-12-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Irpagratinib?
Approved indications include: Hepatocellular carcinoma, Solid tumour, Liver cancer.
When does the Irpagratinib patent expire?
No public expiry year is available for Irpagratinib yet; this page updates once verified.
How do I get a quote for Irpagratinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06